1. Home
  2. ERAS vs CSR Comparison

ERAS vs CSR Comparison

Compare ERAS & CSR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Erasca Inc.

ERAS

Erasca Inc.

HOLD

Current Price

$9.53

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Logo D/B/A Centerspace

CSR

D/B/A Centerspace

HOLD

Current Price

$64.29

Market Cap

1.1B

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
ERAS
CSR
Founded
2018
1970
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Real Estate Investment Trusts
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.1B
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
ERAS
CSR
Price
$9.53
$64.29
Analyst Decision
Strong Buy
Buy
Analyst Count
9
7
Target Price
$5.33
$70.50
AVG Volume (30 Days)
7.9M
146.2K
Earning Date
11-12-2025
02-17-2026
Dividend Yield
N/A
4.76%
EPS Growth
N/A
N/A
EPS
N/A
1.82
Revenue
N/A
$273,450,000.00
Revenue This Year
N/A
$6.83
Revenue Next Year
N/A
$3.14
P/E Ratio
N/A
$35.46
Revenue Growth
N/A
5.72
52 Week Low
$1.01
$52.76
52 Week High
$9.87
$69.15

Technical Indicators

Market Signals
Indicator
ERAS
CSR
Relative Strength Index (RSI) 88.98 42.61
Support Level $3.36 $64.32
Resistance Level $6.49 $67.74
Average True Range (ATR) 1.01 1.83
MACD 0.57 -0.34
Stochastic Oscillator 92.85 15.99

Price Performance

Historical Comparison
ERAS
CSR

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.

About CSR D/B/A Centerspace

Centerspace is a real estate investment trust (REIT) that focuses on the ownership, management, acquisitions, redevelopment, and development of apartment communities. The company operates through a single reportable segment which includes the ownership, management, development, redevelopment, and acquisition of apartment communities and conduct their corporate operations from offices in Minot, North Dakota and Minneapolis, Minnesota.

Share on Social Networks: